Xinyu Hospital of Traditional Chinese Medicine, Xinyu.
Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine.
Medicine (Baltimore). 2021 Jan 15;100(2):e24179. doi: 10.1097/MD.0000000000024179.
Migraine is a clinically high incidence rate of neurovascular disease. It is a recurrent headache. It is characterized by nausea, vomiting, fear of voice, and photophobia. Nowadays, a large number of randomized controlled clinical studies have shown that Chinese patent medicine has the advantages of good curative effect and high safety in the treatment of migraine. However, due to the variety of proprietary Chinese medicines, their relative effectiveness and safety have not yet been verified. Therefore, this study will use the network meta-analysis method to verify the effectiveness and safety of different kinds of Chinese patent medicines in the treatment of migraine.
All randomized controlled trials of Toutongning capsule, Yangxue Qingnao granule, naoxintong capsules, Tianmagouteng granules in the treatment of migraine were searched from PubMed, Cochrane Library, web of science, EMBASE, sinomed, CNKI, Wanfang database, VIP. The retrieval time is from the establishment of the database to November 18, 2020. In order to avoid omission, we will manually retrieve relevant references and conference papers. According to the inclusion and exclusion criteria, we evaluated the quality and risk of all the retrieved literatures. Methodological quality assessment and bias risk will be assessed using the Cochrane bias risk tool. Revman 5.3, WinBUGS 1.4.3, and stata14.2 software will be used for all data analysis.
This study will directly or indirectly compare the effectiveness of different interventions on migraine outcome indicators, and rank the effectiveness. The main outcome measures included total effective rate (total effective rate = rocovery + obvious effective + effective/total number of cases × 100%), visual analogue scale (VAS) score, and secondary outcome indicators included analgesic effect evaluation index and quality of life scale.
To provide evidence for evidence-based medicine and clinical researchers to choose more effective Chinese patent medicines to treat migraine.
偏头痛是一种临床发病率较高的神经血管性疾病。它是一种反复发作的头痛，其特征是伴有恶心、呕吐、畏声、畏光。目前，大量的随机对照临床试验表明，中成药在偏头痛的治疗中具有疗效好、安全性高的优点。然而，由于中成药种类繁多，其相对有效性和安全性尚未得到验证。因此，本研究将采用网状 Meta 分析方法验证不同种类的中成药治疗偏头痛的有效性和安全性。
从 PubMed、Cochrane 图书馆、Web of Science、EMBASE、sinomed、CNKI、万方数据库、VIP 中检索 Toutongning 胶囊、养血清脑颗粒、脑心通胶囊、天麻钩藤颗粒治疗偏头痛的所有随机对照试验。检索时间从数据库建立到 2020 年 11 月 18 日。为避免遗漏，我们将手动检索相关参考文献和会议论文。根据纳入和排除标准，我们评估了所有检索文献的质量和风险。采用 Cochrane 偏倚风险工具评估方法学质量和偏倚风险。Revman 5.3、WinBUGS 1.4.3 和 stata14.2 软件将用于所有数据分析。
本研究将直接或间接比较不同干预措施对偏头痛结局指标的疗效，并对疗效进行排序。主要结局指标包括总有效率（总有效率=痊愈+显效+有效/总例数×100%）、视觉模拟评分（VAS）评分，次要结局指标包括镇痛效果评价指标和生活质量量表。
为循证医学和临床研究人员提供选择更有效的中成药治疗偏头痛的证据。
